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Abstract
Background:	Patient-	directed	knowledge	tools	such	as	patient	versions	of	guidelines	
and	 patient	 decision	 aids	 are	 increasingly	 developed	 to	 facilitate	 shared	 decision	
making.	In	this	paper,	we	report	how	consensus	was	reached	within	the	Netherlands	
on	quality	criteria	for	development,	content	and	governance	of	these	tools.
Method:	A	12-	month	development	and	consensus	study.	The	consortium	worked	on	
four	work	packages:	(a)	reviewing	existing	criteria;	(b)	drafting	the	quality	criteria;	(c)	
safe-	guarding	 the	acceptability	and	feasibility	of	 the	draft	criteria	by	participatory	
research	in	on-going	tool	development	projects;	and	(d)	gaining	formal	support	from	
national	stakeholders	on	the	quality	criteria.
Results:	We	reached	consensus	on	a	8-	step	guidance;	describing	minimal	quality	cri-
teria	for	(a)	the	team	composition;	(b)	setting	the	scope;	(c)	identifying	needs;	(d)	the	
content	and	format;	(e)	testing	the	draft;	(f)	finalizing	and	approval;	(g)	dissemination	
and	application,	and	(h)	ownership	and	revision.	The	participants	of	the	on-going	tool	
development	projects	were	positive	about	the	quality	criteria	in	general,	but	divided	
as	 to	 the	degree	of	detail.	Whereas	 some	expressed	a	 clear	desire	 for	procedural	
standards,	others	felt	that	it	would	be	sufficient	to	provide	only	general	directions.	
Despite	 the	 different	 views	 as	 to	 the	 degree	 of	 detail,	 consensus	was	 reached	 in	
three	stakeholder	meetings.
Discussion:	We	successfully	collaborated	with	all	stakeholders	and	achieved	formal	
support	from	national	stakeholders	on	a	set	of	minimum	criteria	for	the	development	
process,	content	and	governance	of	patient-	directed	knowledge	tools.
K E Y W O R D S
clinical	practice	guidelines,	patient	decision	aids,	patient	information,	patient	involvement,	
patient	participation,	patient	versions	of	guidelines,	quality	standards,	shared	decision	making
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1  | INTRODUC TION
The	 knowledge	 in	 health	 care	 is	 expanding	 daily—so	 that	 keeping	
up	with	knowledge	is	a	challenge.1	The	development	of	knowledge	
tools	is	intended	to	support	clinicians	to	keep	pace	and	to	improve	
their	decision	making.	Many	knowledge	tools	such	as	clinical	prac-
tice	guidelines,	protocols	or	clinical	pathways	have	been	developed	
over	 the	years.2	With	 the	 increasing	call	 for	 a	patient	 revolution,3 
further	tool	types	have	been	added	to	the	mix,	including	patient	de-
cision	aids.	A	key	source	of	information	for	patient-	directed	knowl-
edge	tools	is	clinical	practice	guidelines.	Clinical	practice	guidelines	
summarize	 research	 evidence	 systematically	 and	 provide	 recom-
mendations	on	a	specific	clinical	topic.4	Nowadays,	the	GRADE	ap-
proach	 is	used	as	a	 framework	 to	 rate	 the	quality	of	 the	evidence	
and	to	assess	the	strength	of	the	recommendations	taking	into	ac-
count	 the	balance	between	benefits	 and	harms,	 resource	use	 and	
feasibility	considerations.	The	GRADE	method	also	recognizes	 the	
collective	patient	perspectives;5	 the	strength	of	 the	 recommenda-
tions	is	also	affected	by	the	patients’	appreciation	of	advantages	and	
level	of	acceptability	of	disadvantages	of	the	 intervention,	such	as	
side-effects	and	treatment	burden.	Worldwide,	patients	and	patient	
representatives	increasingly	take	part	in	the	development	of	guide-
line	recommendations.6
Next	 to	 patient	 participation	 on	 a	 collective	 level,	 efforts	 are	
made	 to	 adapt	 or	 enrich	 guidelines	 so	 as	 to	 facilitate	 patient	 par-
ticipation	on	an	individual	level,	in	clinical	decision	making.7	Patient	
participation	is	especially	important	in	case	of	preference-	sensitive	
decisions	where	multiple	 options	 exist	 or	where	 the	 benefits	 and	
harms	 of	 the	 intervention	may	 be	 assigned	 a	 different	 weight	 by	
different	patients.8	Illustrative	examples	to	facilitate	patient	partic-
ipation	 in	 clinical	 decision	making	 are	patient	 versions	of	 a	 guide-
line	 such	 as	 a	 lay	 summary,	 or	 patient	 decision	 aids	 for	 specific	
preference-	sensitive	decisions	attached	to	the	guideline	document.	
Some	 guidance	 for	 the	 content	 of	 lay	 summaries	 of	 guidelines	 is	
provided	by	the	Guidelines	 International	Network.9	 In	2006,	stan-
dards	were	 formulated	 for	 the	 content	of	patient	decision	aids	by	
the	 International	 Patient	 Decision	 Aids	 Standards	 (IPDAS)	 group,	
a	 multistakeholder	 process	 that	 led	 to	 a	 self-	assessment	 check-
list.10	Further	work	 led	to	a	measure	 IPDASi11	and	a	set	of	criteria	
that	should	be	met	to	achieve	a	“minimum”	acceptable	standard.12 
Guideline	 developers	 are	 experimenting	 to	 derive	 the	 information	
for	patient	decision	aids—evidence	on	benefits	and	harms	of	 inter-
ventions	and	on	patient	considerations	and	patient	preferences—di-
rectly	from	the	guideline.13
Much	is	also	happening	with	respect	to	development	of	patient-	
centred	knowledge	tools	such	as	patient	versions	of	a	guideline	or	
patient	decision	aids	in	the	Netherlands,	on	various	sides	of	the	care	
equation.14	Patient	organizations	are	gaining	a	more	accurate	picture	
of	the	information	needs	that	these	tools	must	satisfy.	Professional	
and	scientific	associations	feel	a	responsibility	to	ensure	the	accu-
racy	 and	 effectiveness	 of	 medical	 information	 supplied	 via	 such	
tools.	Web	and	tool	designers	continue	to	introduce	ever	more	user-	
interface	friendly	tools.
For	 this	 study,	we	 used	 the	 following	 definition:	 a	 patient-	
directed	 knowledge	 tool	 synthesizes	 and	 distils	 the	 highest	
quality	knowledge	and	research,	is	aimed	directly	at	the	patient	
(and	next	of	kin),	with	the	goal	to	engage	patients	in	dialogue	or	
deliberation	during	a	clinical	encounter	or	to	support	and/or	im-
prove	patient	decision	making	which	may	or	may	not	take	place	
during	 a	 clinical	 encounter.15	 Yet	 these	patient-	centred	 knowl-
edge	tools	are	subject	to	a	multitude	of	varying	definitions	and	
criteria,	especially	 regarding	the	patient	versions	of	guidelines,	
and	the	development	process.16-22	As	a	 result,	 it	 is	difficult	 for	
parties	to	distinguish	what	is	truly	important	from	what	is	not	or	
what	type	of	patient-	directed	knowledge	tool	is	in	fact	the	cor-
rect	means	to	achieve	the	stated	purpose.	In	addition	to	quality	
criteria,	 the	 need	 for	 national	 governance	 is	 also	 felt	 strongly,	
as	 many	 initiatives	 by	 patient	 organizations	 and	 professional	
bodies	 to	 develop	 patient-	directed	 knowledge	 tools	 exist	 side	
by	 side.	This	 situation	has	 resulted	 in	an	uncoordinated,	partly	
overlapping	 mixture	 of	 publicly	 and	 privately/commercially	
available	patient	decision	aids.23	Moreover,	some	of	the	patient	
decision	 aids	 do	 not	 seem	 to	 follow	 the	 rigid	 and	 multistake-
holder	methods	 to	 review	 the	 evidence	 base,	 as	 is	 common	 in	
clinical	practice	guidelines.
A	guidance	 for	 the	development	of	 reliable	patient	versions	of	
guidelines	and	patient	decision	aids	can	serve	to	integrate	all	existing	
knowledge	and	previously	developed	expertise,	allowing	the	stake-
holders	to	work	together	more	effectively	and	more	efficiently.	The	
purpose	of	such	a	guidance	is	to	promote	the	development	of	high-	
quality,	 reliable	 and	 publicly	 available	 patient-	directed	 knowledge	
tools,	which	will	contribute	to	achieving	properly	informed	patients	
and	shared	decision	making.
Initiated	 by	 the	 National	 Health	 Care	 Institute	 of	 the	
Netherlands,	 a	 consortium	of	 healthcare	 stakeholders	 started	 to	
develop	such	guidance,	supported	by	academic	researchers.	Apart	
from	validity,	feasibility	was	important	given	the	conflict	between	
the	aim	of	high-	quality	knowledge	tools	and	the	limited	resources	
to	develop	such	tools.	The	purpose	of	this	article	is	twofold.	First,	
we	describe	 the	methods	used	 for	 arriving	at	 the	guidance	 as	 an	
illustrative	 example	 of	 how	 formal	 support	 from	 national	 stake-
holders	can	be	reached.	Second,	we	present	the	list	 (guidance)	of	
minimum	 quality	 criteria	 for	 the	 development,	 content	 and	 gov-
ernance	of	patient	information	on	guidelines	and	patient	decision	
aids,	as	well	as	the	way	in	which	these	tools	can	be	connected	to	
the	clinical	practice	guidelines.
2  | METHODS
The	National	Health	Care	Institute	of	the	Netherlands	initiated	and	
granted	this	12-	month	development	study	that	was	composed	of	a	
literature	review,	a	feasibility	check	and	a	consensus	procedure.	We	
took	 the	position	 that	we	needed	various	 types	of	 input	and	pro-
cesses	to	ensure	a	successful	consensus	process.	To	this	end,	we	de-
signed	a	consortium	(see	first	four	authors	and	last	two	authors)	that	
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worked	 together	 continuously	 in	 an	 iterative	 process	 using	 cross-	
fertilization,	without	being	hindered	by	hierarchy.	A	representative	
of	the	Dutch	Federation	of	Patients’	Organisations	(last	author)	was	
co-	leading	the	project	with	the	first	author.
In	 a	 12-	month	 project	 that	 started	 in	 October	 2015,	 we	
worked	 on	 the	 basis	 of	 four	 work	 packages	 (WPs):	 (WP1)	
Radboud	University	(MF)	reviewed	existing	criteria	 in	the	litera-
ture,	synthesizing	evidence	and	best	practices;	(WP2)	Maastricht	
University	 (TvdW,	 DD),	 the	 coordinating	 group,	 developed	 the	
drafts	 of	 the	 guidance;	 (WP3)	 NIVEL	 (NB)	 safeguarded	 the	 ac-
ceptability	and	feasibility	of	the	draft	criteria	by	gathering	expe-
riences	with	the	draft	guidance	from	knowledge	tool	developers;	
(WP4)	the	Dutch	Federation	of	Patients’	Organisations	(AK)	orga-
nized	the	consensus	procedure	aiming	to	support	the	guidance	by	
national	stakeholders.
(WP1)	We	searched	for	formal	criteria	and	methodologies	in	the	
scientific	literature,	in	policy	reports,	and	on	websites	by	developers	
of	guidelines	and	patient	decision	aids.	The	search	strings	that	we	
used	to	explore	PubMed	are	described	in	Table	1,	as	are	the	websites	
to	search	for	the	grey	literature.	This	inventory	supplied	the	basis	for	
the	first	draft	of	the	guidance.	One	of	the	researchers	of	WP1	made	
a	 first	 selection	of	 the	search	based	on	 title	and	abstract,	and	ex-
cluded	references	clearly	not	fulfilling	the	inclusion	criteria.	All	full-	
text	versions	that	resulted	from	this	first	selection	were	downloaded	
and	 assessed	 along	 the	 pre-	set	 inclusion	 and	 exclusion	 criteria.	 In	
case	of	doubt,	a	second	researcher	was	consulted	to	reach	consen-
sus	on	inclusion	or	exclusion.
Inclusion	criteria	for	literature	on	patient	versions	of	guidelines:
•	 The	paper	describes	the	development	process	of	a	patient	version	
or	lay	summary	of	a	clinical	practice	guideline.
•	 Explicit	description	of	the	methods	used	(be	it	short	or	extensive)	
for	development.
•	 English	or	Dutch	language.
Exclusion	criteria:
•	 Papers	describing	only	the	process	of	patient	participation	in	the	
development	of	a	clinical	practice	guideline.
Inclusion	criteria	for	literature	on	patient	decision	aids:
•	 The	title	reports	the	term	“development”	or	“design.”
•	 The	abstract	reports	the	development	of	a	patient	decision	aid	as	
the	aim	of	the	paper.
•	 Description	of	the	development	process	of	disease-specific	or	ge-
neric	decision	aids.
•	 Explicit	description	of	the	methods	used	(be	it	short	or	extensive)	
for	development.
•	 English	or	Dutch	language.
Exclusion	criteria:
•	 Papers	describing	the	development	of	tools	that	stretch	further	
than	patient	decision	aids	(eg,	social	support	and	self-management).
•	 Papers	 describing	 the	 development	 of	 tools	 on	 other	 decisions	
than	medical	decisions.
(WP2)	 The	 project	was	 coordinated	 via	monthly	meetings	 of	 all	
WP	 leaders,	 complemented	 by	 numerous	 one-	to-	one	 contacts.	We	
used	definitions	of	the	patient-	directed	knowledge	tools	that	were	re-
cently	formulated	in	another	Dutch	national	consensus	procedure;	see	
Box	1.24,25	The	findings	from	the	literature	review	were	used	to	draft	
the	first	set	of	 the	minimal	quality	criteria	 for	development,	content	
and	governance	of	patient-	directed	knowledge	tools.	The	findings	of	
the	feasibility	checks	(WP3)	and	consensus	meetings	(WP4)	were	used	
to	write	the	second	and	third	draft	of	the	guidance.
(WP3)	The	first	and	second	draft	guidance	was	presented	for	
a	critical	assessment	of	its	feasibility	to	the	project	leaders	of	nine	
working	groups	 tasked	with	 the	development	of	patient	versions	
of	guidelines	or	patient	decision	aids	along	clinical	practice	guide-
lines.	These	working	groups	were	at	that	time	in	various	phases	of	
their	development	projects.	Five	projects	 focused	on	developing	
patient	information	based	on	guidelines,	for	example	for	patients	
with	 inflammatory	 bowel	 disease.	 Four	 projects	 focused	 on	 de-
veloping	 patient	 decision	 aids	 for	 specific	 recommendations,	 for	
TABLE  1 Search	strings	used	to	explore	PubMed	and	websites	
used	to	search	for	grey	literature
Search	strings
	Patient	information	based	on	guidelines
•	(((method*[Title/Abstract]	OR	approach*[Title/Abstract]	OR	
framework[Title/Abstract]	OR	develop*[Title/Abstract]	OR	
creat*[Title/Abstract]))	AND	(“patient	version*”[Title/Abstract]	
OR	“information	for	the	public”[Title/Abstract]	OR	“public	
information”[Title/Abstract]	OR	“patient	booklet*”[Title/
Abstract]	OR	booklet*[Title/Abstract]))	AND	(“clinical	practice	
guideline*”	OR	“Practice	Guidelines	as	Topic”[Mesh]	OR	“quality	
standard*”)
•	(“Practice	Guidelines	as	Topic”[Mesh]	OR	“Practice	Guideline”	
[Publication	Type]	OR	guideline*)	AND	“patient	version”	AND	
develop*
	Patient	decision	aids
•	“Decision	Support	Techniques”[Majr:NoExp]	AND	(method*[tiab]	
OR	approach*[tiab]	OR	framework[tiab]	OR	develop*[tiab]	OR	
creat*[tiab])	AND	(“Patient	Satisfaction”[Mesh]	OR	“Patient	
Participation”[Mesh]	OR	“Patient-Centered	Care”[Mesh]))
Websites
•	Dutch	Knowledge	Institute	of	Medical	Specialists
•	Netherlands	Comprehensive	Cancer	Organisation
•	Guidelines	International	Network,	Patient	and	Public	Involvement	
working	group
•	UK	National	Institute	for	Health	and	Care	Excellence	(NICE)
•	German	Ärztliches	Zentrum	für	Qualität	in	der	Medizin	(ÄZQ)
•	Finnish	Duodecim
•	Australian	National	Health	and	Medical	Research	Council	
(NHMRC)
•	USA	Oncoline	Kaiser
•	USA	Agency	for	Healthcare	Research	and	Quality	(AHRQ)
•	Canadian	Task	Force	on	Preventive	Health	Care	(CTFPHC)
•	IPDAS	working	Group	www.ipdas.ohri.ca
•	Patient	Decision	Aids	Research	Group	https://decisionaid.ohri.ca
•	The	Preference	Laboratory	http://optiongrid.org/option-grids/
about-the-grids
•	Mayo	Clinic	for	shared	decision	making	http://shareddecisions.
mayoclinic.org
•	DECIDE	research	Group	www.decide-collaboration.eu
•Joanna	Briggs	Institute	University	of	Adelaide	http://joannabriggs.
org
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example	 in	 the	care	 for	orthopaedic	patients.	For	 the	 third	draft	
of	 the	 guidance,	we	did	 not	 only	 seek	 for	 critical	 assessment	 by	
the	project	leader,	but	we	also	asked	the	project	leader	to	actually	
apply	 (part	of)	the	guidance	steps	 in	their	working	groups	and	to	
report	about	their	experiences.	Four	of	these	nine	on-going	proj-
ects	were	further	analysed	by	means	of	outreach	visits	and	partic-
ipatory	observations	of	working	group	meetings.	Finally,	 the	 last	
draft	and	the	experiences	were	fed	back	to	each	project	leader	in	
individual	 semi-	structured	 qualitative	 interviews.	 The	 interviews	
were	audiotaped,	transcribed	and	analysed	with	thematic	content	
analysis.26
(WP4)	The	draft	versions	of	the	guidance	were	discussed	in	three	
invitational	meetings.	We	purposefully	sampled	the	participants	for	
the	first	two	meetings	to	guarantee	continuity	in	the	process	by	in-
viting	a	core	group	for	both	meetings.	While	we	planned	the	input	
from	 academic	 experts	 in	 the	 first	meeting,	 the	 profile	 of	 partici-
pants	gradually	shifted	to	stakeholders	representing	end-	users	only	
in	the	last	meeting.
First,	a	2-	hour	expert	meeting	was	held	 in	March	2016	aimed	
at	 collecting	 the	experts’	 suggestions,	 for	which	43	 stakeholders	
representing	 patients,	 care	 providers,	 researchers,	 web	 and	 tool	
designers	and	healthcare	 insurers	were	 invited.	Second,	a	2-	hour	
meeting	was	held	in	June	2016,	for	which	29	stakeholders	repre-
senting	patients,	care	providers,	knowledge	institutions,	healthcare	
insurers	and	the	government	were	invited	to	question	their	support	
to	the	draft	version	of	the	guidance.	Third	and	finally,	a	90-	minute	
consensus	meeting	was	 held	 in	 September	 2016,	 for	which	 only	
the	 formal	 representatives	 of	 patients,	 healthcare	 providers	 and	
healthcare	insurers	were	invited	in	order	to	gain	formal	support.
3  | RESULTS
3.1 | How did we arrive at the guidance?
3.1.1 | (WP1) Inventory of existing methods and 
criteria in scientific and grey literature
We	 found	51	hits	 in	PubMed,	of	which	 four	 studies	were	 included	
that	 describe	 criteria	 for	 developing	 patient	 versions	 of	 guidelines	
(see	Appendix	S1).	The	grey	literature	revealed	many	websites	pub-
lishing	patient	versions	of	guidelines,	but	 information	on	how	these	
knowledge	 tools	were	developed	was	 scarce.	Detailed	descriptions	
were	found,	however,	in	the	Guidelines	International	Network	“G-	I-	N	
Public	toolkit	on	patient	and	public	involvement	in	guidelines.”	For	de-
veloping	patient	decision	aids,	we	found	385	hits	in	PubMed,	of	which	
24	studies	were	included;	10	more	relevant	publications	were	added	
by	the	experts	in	the	project	group	(see	Appendix	S1).	In	addition,	the	
websites	revealed	rich	data	on	what	exactly	patient	decision	aids	are	
and	how	they	should	be	developed.
The	criteria	for	the	content	of	patient	decision	aids	were	mostly	
based	on	 empirical	 data,27	while	 such	data	were	more	or	 less	 ab-
sent	for	the	content	of	patient	versions	of	guidelines.	IPDAS	criteria	
(ipdas.ohri.ca)	enjoy	broad	support	where	criteria	for	the	content	of	
decision	aids	are	concerned,	due	to	their	substantiation	by	means	of	
systematic	consensus	methodology.
3.1.2 | (WP3) Feasibility assessment in on-going 
development projects
While	 reactions	 to	 the	 ordering	 of	 the	 development	 steps	 in	 the	
draft	guidance	were	unanimously	positive,	the	project	leaders	were	
extremely	 divided	 as	 to	 the	 degree	 of	 detail	when	 it	 came	 to	 the	
instructions	within	 the	steps	of	 the	guidance,	 such	as	how	best	 to	
map	 the	patient	perspective	 in	 the	scoping	and	needs	assessment	
phase.	Whereas	some	project	 leaders	expressed	a	clear	desire	 for	
procedural	standards	(it should be clear at all times who does what and 
when),	others	felt	that	it	would	be	sufficient	for	the	instructions	in	
each	step	 to	provide	only	general	direction.	Concerning	 the	other	
issues	raised,	we	report	those	most	frequently	mentioned:
•	 Deviating	from	the	linear	ordering	of	the	guidance	should	be	pos-
sible.	For	example,	the	guideline	working	group	may	be	no	longer	
active,	while	the	patient-directed	tool	is	urgently	needed.
•	 Language	and	jargon	used	in	the	guidance	were	often	found	to	be	
too	academic.
•	 The	amount	and	complexity	of	the	work	to	map	the	patients’	per-
spective	in	the	scoping	and	needs	assessment	phase,	for	example	
by	organising	a	focus	group	or	a	questionnaire	survey,	were	often	
underestimated.	 Due	 to	 limitations	 in	 resources	 and	 the	 high	
workload,	work	should	not	be	done	twice,	 in	the	guideline	work-
ing	group	and	 in	 the	patient	 tool	development	group.	Moreover,	
the	 required	 minimum	 number	 of	 two	 patients	 in	 the	 team—as	
was	prescribed	in	the	earlier	drafts—was	a	concern,	as	well	as	the	
Box  1 The  Dutch  definitions  of  the  patient- directed 
knowledge tools24,25
Patient information based on a guideline	 (=patient	 version	 of	 a	
guideline):	Explanation	of	a	 specific	 condition	or	 (health)	 care	
issue	based	on	a	guideline;	made	available	to	patients	and	their	
next	of	kin;	provides	information	on	available	care	choices	and	
the	care	that	they	can	expect	from	the	care	process.
Summary of guideline:	Concise	overview	of	 the	guideline,	pro-
viding	 main	 conclusions	 and	 recommendations	 in	 clear	 and	
simple	language;	can	be	applied	in	practice	independently	from	
the	guideline;	intended	for	both	care	providers	and	patients.
Patient decision aid (PDA):	Auxiliary	information	and	answers	to	
frequently	 asked	 questions	 for	 patients	when	 choosing,	with	
their	care	providers,	from	different	options—including	the	op-
tion	to	forgo	care—in	a	specific	area	such	as	diagnostics,	treat-
ment,	screening,	counselling	or	aftercare;	discusses	the	possible	
outcomes	and	effects	of	each	option—desirable	or	otherwise—
and	 their	 likelihood	 of	 occurring;	 helps	 patients	 to	 weigh	 up	
their	options	based	on	their	own	values,	standards	and	personal	
circumstances.
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mandatory	 inclusion	of	a	representative	of	the	guideline	working	
group.
•	 Formal	authorization	of	the	tool	was	not	regarded	necessary	by	
all	stakeholders,	with	the	argument	that	the	guideline	was	already	
approved.
•	 All	project	leaders	plead	for	a	central	portal	to	host	the	patient-di-
rected	knowledge	tools,	supported	by	a	national	party	taking	care	
of	the	governance	of	the	tools.
3.1.3 | (WP4) The consensus meetings
For	the	first	meeting,	28	out	of	43	invited	experts	were	present.	
When	asked	to	mark	the	most	important	sections	of	the	guidance,	
experts	prioritized	 the	 following	 issues:	chose	 the	 right	 type	of	
knowledge	tool	for	the	aim	it	pursues;	use	the	guideline	(recom-
mendation)	itself	as	the	most	important	source	of	information	for	
the	knowledge	tool;	determine	who	will	become	the	owner	of	the	
knowledge	 tool;	make	 the	knowledge	 tool	easily	accessible	and	
free	to	use;	and	organize	authorization	by	the	healthcare	profes-
sional	organization(s)	as	well	as	the	patients’	organization(s).
For	the	second	meeting,	21	out	of	29	 invited	were	present.	All	
stakeholders	 were	 well	 represented.	 In	 general,	 they	 expressed	 a	
positive	attitude	towards	the	guidance	although	two	critical	remarks	
were	made.	Firstly,	multiple	stakeholders	emphasized	to	widen	the	
scope	 of	 the	 guidance	 so	 that	 patient-	directed	 knowledge	 tools	
can	 also	 be	 developed	 on	 topics	 that	 are	 not	 covered	 by	 clinical	
practice	 guidelines,	 especially	 patient	 organizations	 claimed	 that	
the	 information	 needs	 of	 patients	 should	 determine	 the	 content	
of	 patient-	directed	 knowledge	 tools,	 as	 opposed	 to	 only	 follow-
ing	 the	 existing	 guideline	 recommendations.	 Secondly,	 the	 nursing	
organization	criticized	the	language	of	the	guidance	being	too	scien-
tific	and	too	much	loaded	with	medical	jargon.
The	third	meeting	was	attended	by	formal	representatives	of	all	
parties	except	for	the	Dutch	Association	of	Insurers,	which	formally	
declined	while	 giving	 blind	 consent	 to	 the	 guidance	 as	 a	 token	 of	
trust	in	the	representatives	of	the	patients	and	providers.	Therefore,	
the	 final	meeting	was	 attended	 by	 four	 participants,	 representing	
the	 Dutch	 Federation	 of	 Patients’	 Organisations	 (HP),	 the	 Dutch	
College	 of	 General	 Practitioners	 (TD),	 the	 Dutch	 Association	 of	
Medical	 Specialists	 (IM)	 and	 the	 Dutch	 Nurses’	 Association	 (SK).	
They	expressed	their	positive	intentions	with	regard	to	supporting	
the	guidance,	but	only	after	the	following	issues	were	clarified:	the	
minimum	criteria	should	clearly	be	listed	separately	from	the	addi-
tional	suggestions;	developers	of	patient-	directed	knowledge	tools	
should	be	encouraged	to	use	the	guidance	according	to	the	comply	
or	explain	principle;	and	authorization	of	patient-	related	knowledge	
tools	should	be	done	on	a	process	level	and	not	on	the	level	of	autho-
rizing	the	content	of	the	tools,	as	content	was	already	authorized	in	
the	final	phase	of	the	guideline	development	process.
In	retrospect,	it	can	be	observed	that	the	quest	for	clear	and	out-
spoken	procedural	 standards	 that	was	 verbalized	by	 some	project	
leaders	in	WP3	was	strongly	echoed	in	the	first	meeting	but	that	it	
faded	away	in	the	second	meeting,	while	only	crude	instructions	for	
each	step	were	regarded	sufficient	in	the	third	and	final	meeting.
3.2 | The guidance
WP1	 provided	 rich	 data	 for	 formulating	 eight	 distinct	 development	
steps	 in	 the	 guidance	 (Table	2).	 The	 final	 guidance	 consists	 of	 three	
components:	 (a)	 recommendations	for	which	type	of	knowledge	tool	
TABLE  2 The	similarities	and	differences	between	the	eight	development	steps	for	(a)	patient	information	on	a	guideline	and	(b)	a	patient	
decision	aid	(PDA)	connected	to	specific	guideline	recommendation(s)
Typical of patient information on a 
guideline(s) Development steps
Typical of PDA connected to specific 
recommendation(s)
1 TEAM
Chose	members	and	define	tasks
Provides	an	overview	of	the	entire	
guideline	(module)
2 SCOPE
Establish	provisional	scope 
Create	inventory	of	existing	versions
Concerns	one	or	several	specific	
recommendations.
Not	a	one-	to-	one	application	of	
guideline.	Information	needs	may	
also	differ	from	those	mentioned	
in	the	guideline
3	NEEDS
Identify	information	needs
Establish	attributes	for	consideration	in	
decision	making. 
Needs	of	care	providers	as	well.
Purposeful	selection	of	guideline	
recommendations
4	CONTENT
Content	and	form
International	criteria	are	in	place;	IPDAS	(Int.	
Pat.	Dec.	Aids	standards)
5 TEST
Testing	the	concept
6 FINALIZING
Finalising	and	obtaining	approval
7 DISSEMINATION
Dissemination	and	application
8 OWNERSHIP
Management	and	revision
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Box 2 The guidance. A brief description of each step for the development of patient information on a guideline or a pa-
tient decision aid (PDA) connected to specific guideline recommendation(s)
1. TEAM	The	team	composition	is	discussed	with	the	relevant	patients’	and	professional	associations.	The	team	has	an	independent	chair	
and	a	process	support	member/secretary,	along	with	at	 least	one	patient(-	representative)	with	first-	hand	experience	(acquired	by	the	
patients’	organization).	Membership	of	the	team	is	approved	based	on	written	Declarations	of	Interests.	An	editor	with	experience	in	
writing	copy	for	a	non-	expert	audience	will	be	involved	in	the	team.	If	the	development	of	the	tool	is	part	of	a	guideline	project,	the	team	
will	(ideally)	be	commissioned	by	the	guideline	working	group	itself,	which	has	budgeted	the	developmental	work.
2. SCOPE	The	team	checks	the	availability	of	existing	tools	and	establishes	the	objective,	the	target	group	and	the	rough	form	of	the	tool.
Patient information:	Determine	where	the	guideline	is	failing	to	meet	patients’	information	needs.	After	all,	guidelines	for	practice	are	typi-
cally	drawn	up	from	the	perspective	of	the	care	provider.	Whenever	possible,	address	the	major	underlying	questions	patients	have	about	
the	guideline,	as	well	as	the	key	recommendations.
PDA:	Select	one	or	more	recommendations	from	the	guideline	that	have	to	do	with	the	decision	at	hand	and	that	are	preference-	sensitive	in	nature.
3.	NEEDS	There	are	multiple	ways	to	identify	the	needs	of	patients:	a	review	of	the	literature,	and/or	additional	qualitative	or	quantitative	
methodologies	for	collecting	data,	such	as	focus	groups	or	questionnaires.
Patient information:	Concerns	any	additional	needs	that	have	not	yet	been	elaborated	during	the	guideline	development,	for	example	with	
regard	to	multimorbidity,	ethnic	minorities,	alternative	interventions	and	self-	management.
PDA:	Involves	questions	the	patients	and	their	proxies	may	have	when	faced	with	taking	a	specific	decision.	Which	needs,	preferences	and	
attributes	influence	a	given	patient’s	decision	making?	This	might	involve	information	needs	and	psychosocial	needs,	along	with	important	
strategies	for	self-	management	in	connection	with	the	illness	or	condition,	and	should	also	include	the	variations	between	patients.
4.	CONTENT	For	both	type	of	tools	describe:
•	 The	target	group	and	medical	condition/symptom/healthcare	topic.
•	 The	guideline(s)	serving	as	the	basis	(in	part)	for	the	creation	of	the	information	on	evidence,	etc.
•	 The	source	of	funding,	who	has	ownership,	year	of	publication	and	expiry	date	(if	applicable).
•	 The	interests	of	each	member	of	the	development	group	(conflict of interest).
Patient information:	Describe	the	guideline	recommendations	on	which	patients	would	want	to	be	informed	in	terms	that	a	layperson	can	
understand.	Mention	frequently	used	examples	of	professional	jargon	so	that	patients	can	become	familiar	with	them.	The	patient	infor-
mation	will	additionally	indicate	the	following	aspects:
•	 Point	out	where	aspects	have	consciously	been	omitted	and/or	emphasis	has	intentionally	shifted	(if	applicable),	as	compared	to	the	guideline.
PDA:	Describe	the	situation/decision	at	hand	and	the	relevant	recommendation(s)	from	the	guideline,	in	terms	that	a	layperson	would	
understand.	The	PDA	will	describe	the	following	aspects	(at	minimum):
•	 An	explanation	that	the	patient	has	a	choice;	that	he/she	is	facing	a	preference-sensitive	decision.
•	 A	description	of	the	medical/care	options,	including	the	option	to	wait	and	see	(if	applicable)	and	an	explanation	of	the	procedure	for	
each	medical/care	intervention.
•	 The	desired	and	undesired	outcomes	(side-effects)	of	the	medical	or	care	options,	and	the	burden	of	treatment.
•	 The	likelihood	and	risks	of	the	outcomes,	expressed	as	numeric	data	with	equal	denominator	of	population	in	natural	frequencies	and	an	
identical	length	of	time;	preferably	displayed	in	population	diagrams;	framed	both	positively	and	negatively	(chances	of	both	survival	and	
fatality,	for	example);	and	in	the	case	of	risk	reduction	presented,	at	minimum,	in	terms	of	absolute	(and	potentially	relative)	risk	reduction.
•	 An	evidence	table	in	which	the	medical/care	options	are	summarized	and	compared	in	terms	of	a	few	key	aspects.
•	 Ensure	explicit	mention	of	the	attributes	found	in	step	3	that	are	important	for	patients	to	keep	in	mind	as	they	consider	their	options	
and	elicit	their	values.	These	attributes	must	contribute	to	the	key	aspects	described	in	the	evidence	table.
5. TEST	The	development	team	will	present	the	draft	to	the	relevant	professional,	scientific	and	patients’	associations	for	the	purpose	of	obtain-
ing	feedback.	The	parties	will	assess	whether	the	patient	perspective	is	sufficiently	reflected,	ensure	understanding	of	people	with	low	literacy,	
and	if	the	medical	content	is	accurate.	If	the	guideline	working	group	is	still	active,	the	draft	will	be	presented	to	that	group	for	feedback	as	well.
6. FINALIZING	The	development	team	establishes	the	final	knowledge	tool	and	presents	it	to	the	relevant	professional,	scientific	and	pa-
tients’	 associations	 for	 approval.	 This	 regards	 approval	 at	 the	 process	 level,	 that	 is	 concerning	 the	 creation	 of	 the	 knowledge	 tool.	
Ownership	is	determined	and	formally	established.
7. DISSEMINATION	The	tool	will	ideally	be	submitted	to	the	National	Health	Care	Institute	as	a	section	of	the	relevant	guideline(s).	The	
knowledge	tool	becomes	accessible	to	the	public	and	is	preferably	made	available	at	a	central	location,	including	points	for	attention	to	
facilitate	the	actual	application/implementation	in	healthcare	practice.
8. OWNERSHIP	The	owner(s)	of	the	knowledge	tool	will	manage	the	tool	and	determine	when	the	information	is	due	to	be	revised:	in	any	case	
when	the	expiry	date	has	been	reached.	Ideally,	the	need	for	revision	of	the	tool	will	be	considered	when	the	guideline	as	a	whole	is	revised.
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(such	as	a	lay	summary	or	decision	aid)	best	fits	the	objectives	of	the	
development	 group;	 (b)	minimum	 criteria	 for	 the	 eight	 development	
steps,	content	and	governance	of	each	tool	(Box	2);	and	(c)	supplemen-
tal,	detailed	and	concrete	suggestions	for	each	step	in	a	second	layer	
of	information	(14	pages	in	total,	not	presented,	available	on	request).	
Developers	deviating	from	these	minimum	criteria	would	have	to	pro-
vide	a	rationale	for	why	a	criterion	does	not	apply	(“comply	or	explain”).	
The	steps	need	not	always	be	followed	in	linear	fashion,	as	the	guidance	
establishes	 the	 criteria	 for	 an	 effective	 development	 process	 rather	
than	laying	out	a	strictly	prescribed	series	of	ordered	steps.	In	the	event	
that	the	development	of	the	knowledge	tool	(patient	information	on	a	
guideline	or	a	patient	decision	aid	based	on	a	specific	guideline	recom-
mendation)	 is	part	of	a	guideline	project,	 the	development	 team	will	
ideally	be	commissioned	by	the	guideline	working	group	itself.
For	patient	versions	of	guidelines,	the	patients’	information	needs	
together	with	the	subject	of	 the	guideline	will	 form	the	basis	 for	 the	
content	of	the	patient	version;	the	guideline	itself	should	be	the	most	
important	source	of	information.	Rather	than	assuming	just	one	guide-
line	as	a	starting	point,	this	situation	might	mean	that	multiple	guidelines	
will	need	to	be	integrated	and	translated	into	a	single	patient	informa-
tion	document,	as	this	process	will	more	effectively	address	the	desires	
and	perceptions	of	the	target	group.	Or,	alternatively,	it	might	mean	that	
only	a	limited	number	of	guideline	modules	will	be	applied	in	creating	
patient	information	documents.	A	need	to	develop	one	or	more	patient	
decision	aids	is	especially	indicated	when	one	or	more	of	the	guideline’s	
key	recommendations	are	preference-	sensitive	in	nature.
4  | DISCUSSION
We	 successfully	 collaborated	 as	 a	 consortium	 of	 researchers	 and	
end-	user	representatives,	with	patient	participation	achieved	at	the	
highest	 level	 of	 involvement,	 to	 achieve	 formal	 support	 from	 na-
tional	stakeholders	on	a	set	of	minimum	criteria	for	the	development	
process,	 content	 and	 governance	 of	 patient-	directed	 knowledge	
tools	related	to	clinical	practice	guidelines.	What	we	provide	is	not	a	
detailed	“recipe”	for	development	but	rather	a	series	of	recommen-
dations	based	on	the	“state	of	the	art”	and	feasibility	considerations.
A	 number	 of	 potential	 limitations	 should	 be	 mentioned.	 Our	
project	was	 explicitly	 embedded	 in	 the	 guideline	 context,	we	 did,	
for	example	not	include	patient	versions	of	systematic	reviews.	The	
guideline	context	may	be	a	limiting	context	for	developing	patient-	
directed	knowledge	tools.	As	the	starting	point	of	a	clinical	practice	
guideline	is	predominantly	the	clinicians’	perspective,	important	is-
sues	for	patients	may	not	be	covered	in	the	guideline.	The	assignment	
from	 the	National	Health	 Care	 Institute	was	 aimed	 specifically	 at	
guidelines	in	the	context	of	curative	health	care.	While	the	literature	
is	unclear	in	this	regard,	it	is	possible	that	the	content	of	the	guidance	
might	have	been	different	had	 representatives	 from	public	health,	
long-	term	and	palliative	health	care	been	included.	One	strength	of	
this	project	 is	 the	 systematic	 approach	and	 involvement	of	 all	 na-
tional	stakeholders,	from	patients	to	policymakers,	with	patient	rep-
resentatives	 in	a	co-	leading	 role.	We	believe	 that	 the	 involvement	
of	 all	 stakeholders	 from	 the	writing	phase	of	 the	project	proposal	
contributed	to	the	successful	collaboration.	Another	strength	of	the	
project	is	that	the	guidance	was	developed	with	prospective	feasibil-
ity	checks	parallel	to	the	nine	on-going	development	projects.
The	 relevance	 of	 patient-	directed	 knowledge	 tools	 being	 publicly	
available	has	also	been	acknowledged	in	the	UK,	with	one	of	the	main	
institutions	developing	guidelines	committed	 to	develop	patient	deci-
sion	aids	based	on	clinical	guidelines.28	The	 relevance	of	 this	process	
was	 recently	 underpinned	 by	 empirical	 evidence	 in	 the	Netherlands.	
The	Dutch	College	of	General	Practitioners	launched	a	non-	commercial	
public	website	in	March	2012	that	provides	easy	access	to	patient	ver-
sions	of	guidelines.	Since	its	launch,	the	website	has	grown	to	become	
one	of	the	most	visited	Dutch	healthcare	websites.	Healthcare	usage	in	
primary	care	seems	to	have	decreased	by	12%	after	the	launch	of	the	
website.29
We	expect	 the	 criteria	 to	evolve	over	 time	as	 they	are	 further	
tested	through	developers	using	patient	versions	of	guidelines	and	
patient	decision	aids,	as	well	as	by	adding	new	tools	to	the	guidance.	
The	next	challenge	will	be	the	effective	implementation	of	the	guid-
ance	as	a	 further	 step	 towards	ensuring	 the	development	of	high-	
quality,	 reliable	 and	 publicly	 available	 patient-	directed	 knowledge	
tools	with	the	support	and	acceptance	of	professional	associations	
(and	alliances),	scientific	associations	and	patients’	organizations.	The	
main	stakeholders	(the	Dutch	Federation	of	Patients’	Organisations,	
the	Dutch	Association	of	Medical	Specialists,	the	Dutch	College	of	
General	Practitioners	and	the	Dutch	Nurses’	Association)	continued	
in	working	together	to	translate	the	guidance	into	a	web-	based	prac-
tical	version,	and	to	arrive	at	consensus	on	a	sustainable	model	for	
the	development,	publication,	governance	and	 financing	of	patient	
decision	aids.	An	important	follow-	up	step	is	to	crosslink	this	guid-
ance	to	the	guidance	for	developers	of	clinical	practice	guidelines.1
Formal	 steps	 towards	 accreditation	 have	 not	 yet	 been	 taken,	 the	
question	being	whether	this	procedure	is	needed	and	is	warranted	given	
the	 current	 level	 of	 evidence.	 In	 December	 2016,	 the	 USA	 National	
Quality	Forum	released	national	standards	for	the	certification	of	patient	
decision	aids.30	The	certification	criteria	are	meant	to	be	used	for	“com-
plete”	patient	decision	aids,	which	are	standalone,	independent	tools	for	
patients	facing	a	clinical	decision.	Our	guidance,	although	not	formulated	
along	the	lines	of	certification	criteria,	is	highly	comparable	with	the	USA	
criteria	in	terms	of	content.	The	only	USA	criterion	that	we	do	not	cover	
is	that	the	patient	decision	aid	should	report	readability	levels.
We	 believe	 that	 this	 study	 can	 be	 seen	 as	 an	 inspirational	
example	for	other	countries	that	are	facing	the	same	challenges	
with	 regard	 to	 the	 development	 and	 governance	 of	 clinician-	
directed	 and	 patient-	directed	 knowledge	 tools	 such	 as	 guide-
lines,	 guideline	 summaries,	 patient	 versions	 of	 guidelines	 and	
patient	decision	aids.
CONFLIC T OF INTERE S T
All	 authors	 are	 involved	 in	 the	 development	 of	 clinical	 practice	
guidelines,	none	of	them	has	any	commercial	 interest,	and	they	all	
stem	from	non-	profit	organizations.
208  |     VAN DER WEIJDEN Et al.
ORCID
Trudy van der Weijden  http://orcid.org/0000-0002-7469-3781 
R E FE R E N C E S
	 1.	 Bastian	 H,	 Glasziou	 P,	 Chalmers	 I.	 Seventy-	five	 trials	 and	 eleven	
systematic	 reviews	 a	 day:	 how	will	 we	 ever	 keep	 up?	 PLoS Med. 
2010;7(9):e1000326.
	 2.	 Brouwers	M,	Stacey	D,	O’Connor	A.	Knowledge	creation:	synthesis,	
tools	and	products.	CMAJ.	2010;182:E68-72.
	 3.	 Richards	T,	Montori	VM,	Godlee	F,	Lapsley	P,	Paul	D.	Let	the	patient	
revolution	begin.	BMJ.	2013;346:f2614.
	 4.	 Qaseem	 A,	 Forland	 F,	 Macbeth	 F,	 et	 al.	 Guidelines	 International	
Network:	toward	international	standards	for	clinical	practice	guide-
lines.	Ann Intern Med.	2012;156:525-531.
	 5.	 Alonso-Coello	P,	Oxman	AD,	Moberg	J,	et	al.	GRADE	Evidence	to	
Decision	(EtD)	frameworks:	a	systematic	and	transparent	approach	
to	 making	 well	 informed	 healthcare	 choices.	 2:	 Clinical	 practice	
guidelines.	BMJ.	2016;353:i2089.
	 6.	 Boivin	A,	Currie	K,	Fervers	B,	et	al.	Patient	and	public	involvement	
in	 guidelines:	 international	 experiences	 and	 future	 perspectives.	
Qual Saf Health Care. 2010;19:e22.
	 7.	 van	 der	 Weijden	 T,	 Pieterse	 AH,	 Koelewijn-van	 Loon	 MS,	 et	 al.	
How	can	clinical	practice	guidelines	be	adapted	to	facilitate	shared	
decision	making?	A	qualitative	key-	informant	study.	BMJ Qual Saf. 
2013;22:855-863.
	 8.	 van	der	Weijden	T,	Boivin	A,	Burgers	J,	Schünemann	HJ,	Elwyn	G.	
Clinical	practice	guidelines	and	patient	decision	aids.	An	inevitable	
relationship.	J Clin Epidemiol.	2012;65:584-589.
	 9.	 G-I-N	Public	Working	Group.	G-I-N	public	toolkit:	patient	and	pub-
lic	involvement	in	guidelines.	2015.
	10.	 Elwyn	G,	O’Connor	A,	Stacey	D,	et	al.	Developing	a	quality	crite-
ria	framework	for	patient	decision	aids:	online	international	Delphi	
consensus	process.	BMJ.	2006;333:417.
	11.	 Elwyn	G,	O’Connor	AM,	Bennett	C,	et	al.	Assessing	the	quality	of	de-
cision	support	technologies	using	the	International	Patient	Decision	
Aid	Standards	instrument	(IPDASi).	PLoS ONE.	2009;4:e4705.
	12.	 Joseph-Williams	N,	Newcombe	R,	Politi	M,	et	al.	Toward	minimum	
standards	 for	 certifying	 patient	 decision	 aids.	Med Decis Making. 
2014;34:699-710.
	13.	 Agoritsas	 T,	 Fog	 Heen	 A,	 Brandt	 L,	 et	 al.	 Decision	 aids	 that	 re-
ally	 promote	 shared	 decision	 making:	 the	 pace	 quickens.	 BMJ. 
2015;350:g7624.
	14.	 van	der	Weijden	T,	Post	H,	Brand	PLP,	et	al.	Shared	decision	mak-
ing,	 a	 buzz-	word	 in	 the	 Netherlands,	 the	 pace	 quickens	 towards	
nationwide	 implementation.	 Z Evid Fortbild Qual Gesundhwes. 
2017;123–124:69-74.
	15.	 Straus	 SE,	 Tetroe	 J,	 Graham	 I.	 Defining	 knowledge	 translation.	
CMAJ.	2009;181(3–4):165-168.
	16.	 Elwyn	G,	Kreuwel	I,	Durand	MA,	et	al.	How	to	develop	web-	based	
decision	support	interventions	for	patients:	a	process	map.	Patient 
Educ Couns.	2011;82:260-265.
	17.	 Coulter	A,	Stilwell	D,	Kryworuchko	 J,	Mullen	PD,	Ng	CJ,	 van	der	
Weijden	T.	A	systematic	development	process	for	patient	decision	
aids.	BMC Med Inform Decis Mak.	2013;13(suppl	2):S2.
	18.	 Hoffman	AS,	Llewellyn-Thomas	HA,	Tosteson	AN,	et	al.	Launching	a	virtual	
decision	lab:	development	and	field-	testing	of	a	web-	based	patient	decision	
support	research	platform.	BMC Med Inform Decis Mak.	2014;14:112.
	19.	 Raats	CJI,	van	Veenendaal	H,	Versluijs	MM,	Burgers	JS.	A	generic	
tool	 for	 development	 of	 decision	 aids	 based	 on	 clinical	 practice	
guidelines.	Patient Educ Couns.	2008;73:413-417.
	20.	 The	Patient	Decision	Aids	Research	Group.	Ottawa	decision	sup-
port	framework.	https://decisionaid.ohri.ca/	Accessed	dec	2016
	21.	 Ng	CJ,	Mathers	N,	Bradley	A,	Colwell	B.	A	 ‘combined	framework’	
approach	to	developing	a	patient	decision	aid:	the	PANDAs	model.	
BMC Health Serv Res.	2014;14:503.
	22.	 Option	Grid	Collaborative.	How	are	Option	Grids	developed?	http://
optiongrid.org/option-grids/about-the-grids.	 Accessed	 December	
15,	2016.
	23.	 Stiggelbout	AM,	van	der	Weijden	T,	de	Wit	MPT,	et	al.	Shared	de-
cision	making:	really	putting	patients	at	the	centre	of	health	care.	
BMJ.	2012;344:e256.
	24.	 Dreesens	D,	Kremer	L,	van	der	Weijden	T.	The	Dutch	chaos	case:	a	
scoping	review	of	knowledge	and	decision	support	tools	available	
to	clinicians	in	the	Netherlands.	Submitted
	25.	 Dreesens	D,	Kremer	L,	Burgers	J,	van	der	Weijden	T.	Lost	in	defini-
tions:	reducing	duplication	of	and	clarifying	knowledge	tools	using	
modified	RAND	Delphi	method.	Submitted.
	26.	 Berg	 BL.	Qualitative Research Methods for the Social Sciences,	 7th	
edn.	New	York:	Pearson	Education	Limited;	2008.
	27.	 Stacey	D,	Légaré	F,	Lewis	K,	et	al.	Decision	aids	for	people	facing	
health	 treatment	 or	 screening	 decisions.	 Cochrane Database Syst 
Rev	2017;(4):CD001431.
	28.	 Leng	G,	Ingham	Clark	C,	Brian	K,	Partridge	G.	National	commitment	
to	 shared	decision	making.	The	only	way	 to	 achieve	 truly	person	
centred	care.	BMJ	2017;359:j4746.
	29.	 Spoelman	WA,	Bonten	TN,	de	Waal	MWM,	et	al.	Effect	of	an	ev-
idence	 based	 website	 on	 healthcare	 usage:	 an	 interrupted	 time-	
series	study.	BMJ Open.	2016;6:e013166.
	30.	 Elwyn	G,	Burstin	H,	Barry	MJ,	et	al.	A	proposal	for	the	development	
of	national	certification	standards	 for	patient	decision	aids	 in	 the	
US.	Health Policy.	2018;122(7):703-706.	
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.
How to cite this article:	van	der	Weijden	T,	Dreesens	D,	Faber	
MJ,	et	al.	Developing	quality	criteria	for	patient-	directed	
knowledge	tools	related	to	clinical	practice	guidelines.	A	
development	and	consensus	study.	Health Expect. 
2019;22:201–208. https://doi.org/10.1111/hex.12843
